"New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes. The study is by Dr Sean Wharton, McMaster University, Hamilton, ON, Canada and Wharton Weight Management Clinic, Burlington, ON, Canada, and colleagues."
"Orforglipron is a small-molecule, oral glucagon-like peptide-1 (GLP-1) receptor agonist. In this phase 3, multinational, randomised, double-blind trial, the authors examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in a 3:3:3:4 ratio) as an adjunct to healthy diet and physical activity for 72 weeks. All the patients had obesity but not diabetes."
Orforglipron is a small-molecule, oral GLP-1 receptor agonist administered once daily at 6 mg, 12 mg, or 36 mg. A phase 3, multinational, randomised, double-blind trial tested orforglipron versus placebo as an adjunct to healthy diet and physical activity for 72 weeks in people with obesity without type 2 diabetes. Daily orforglipron produced substantial weight loss, with mean reductions exceeding 10% and nearly one in five participants losing 20% or more; many participants achieved reductions beyond 15–20%. The pill also improved key health markers, and oral administration may increase access, affordability, and patient acceptability compared with injectable therapies.
Read at ScienceDaily
Unable to calculate read time
Collection
[
|
...
]